1-7 of 7
Jacob D. Bitran
Close
Sort by
Journal Articles

Is Initial Dasatinib-Blinatumomab Therapy for Ph-Positive ALL in Adults Cost Effective?

Jacob D. Bitran, Edward Nabrinsky, Shams Bufalino, Phillip Knouse, Angel G. Galvez
Journal: Blood
Blood (2021) 138 (Supplement 1): 4962.
https://doi.org/10.1182/blood-2021-144656
Published: 2021
Journal Articles

Idiopathic Erythrocytosis: Vascular Complications

Abdullah Malas, Shams Bufalino, Christie Hancock, Jacob D. Bitran
Journal: Blood
Blood (2021) 138 (Supplement 1): 4146.
https://doi.org/10.1182/blood-2021-148870
Published: 2021
Journal Articles

Risk Factors for the Development of Cardiac Arrhythmias during Hematopoietic Stem Cell Transplantation

Christopher Kapolas, PharmD, Jane Kosirog-Glowacki, PharmD, Kathryn L Barney, NP, Linda Advincula, NP, Leonard M. Klein, MD, Jacob D. Bitran, MD, Shams Bufalino, Tulio E Rodriguez, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3387.
https://doi.org/10.1182/blood-2018-99-120189
Published: 2018
Journal Articles

MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma

David J. Andorsky, MD, Abdulraheem Yacoub, MD, Jacob D. Bitran, MD, Jason Melear, MD, Heather D. Brooks, MD BS, BA, Kenneth A. Foon, MD, Syed Rizvi, MD, Mary Llorente, Jiahui Li, PhD, Jeff P. Sharman, MD
Journal: Blood
Blood (2016) 128 (22): 1798.
https://doi.org/10.1182/blood.V128.22.1798.1798
Published: 2016
Journal Articles

A Retrospective Study to Evaluate the Incidence and Severity of Peripheral Neuropathy for Relapsed/Refractory Multiple Myeloma Patients upon Retreatment with Bortezomib

James R. Berenson, MD, Jacob D. Bitran, MD, Imad Tabbara, MD FACP, Jose Lutzky, MD, Laura V. Stampleman, MD, Sikander Ailawadhi, MD, Ronald Steis, MD, Mehdi M. Moezi, MD
Journal: Blood
Blood (2014) 124 (21): 3469.
https://doi.org/10.1182/blood.V124.21.3469.3469
Published: 2014
Journal Articles

Patterns of Care in Follicular Lymphoma (FL): Are Minorities Being Treated Differently? Report from the National LymphoCare Study (NLCS).

Chadi Nabhan, MD, FACP, Ewelina Morawa, MD, Jacob D. Bitran, MD, FACP, Michael D. Taylor, PhD, Ming Lin, Elaine K. Wong, MD, John Hainsworth, MD
Journal: Blood
Blood (2007) 110 (11): 367.
https://doi.org/10.1182/blood.V110.11.367.367
Published: 2007
Journal Articles

Clofarabine (CLO) Is Active in Patients (pts) with Refractory and/or Relapsed Non-Hodgkin’s Lymphoma (NHL): A Phase I/II Study.

Chadi Nabhan, MD, FACP, Walter Fried, MD, Angel G. Galvez, MD, PhD, Parameswaran Venugopal, MD, Phillip Gozun, Jacob D. Bitran, MD, FACP
Journal: Blood
Blood (2007) 110 (11): 4462.
https://doi.org/10.1182/blood.V110.11.4462.4462
Published: 2007